Alethiomics is an Oxford University spin-out applying innovations in single-cell multi-omic analysis to the development of novel therapeutics for myeloproliferative neoplasms (MPNs).

MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. While currently available treatments can relieve symptoms, they do not tackle the underlying disease drivers meaning patients have poor prognosis.

The company’s founders have pioneered the use of single-cell multi-omics approaches to better understand the biology of MPNs and to discover novel molecular targets as the basis for drug discovery. They have also developed bespoke platforms for target validation to accelerate successful translation to the clinic.

The Alethiomics TARGET-seq platform simultaneously detects DNA mutations, the RNA transcriptome and cell surface proteins from individual cells to provide a holistic understanding of pathologies and more intelligent target identification. Based on these discoveries, the company is now developing therapeutics that it will advance through discovery to clinical development.

Founded in 2021, the company has received £6m in seed financing from Oxford Science Enterprises.

Subscribe for alerts on new companies featured on Startups.Bio